{"title":"Selected concepts on ethics in biopharmaceutical innovation","authors":"Kadour Ghanemi, Shuangsheng Yan","doi":"10.15406/mojpb.2017.06.00204","DOIUrl":null,"url":null,"abstract":"Responsible research and innovation (RRI) is among the most important issues that have generated a huge debate within the political and social milieu, which became an overall case for the biggest EU Research and innovation program ever Horizon [1]. Responsible research and innovation is among the important doctrines for the sustainability of the company [2]. Ethics and the biopharmaceutical responsible innovation is a paradigm of a sector where the ethics and responsibility of health professionals is inevitably linked to public and private life. The biopharmaceutical research, development and marketing responsibilities are taken by the pharmacists, directors and managers of the biopharmaceutical company, all are a combined healthcare team which work together and have a lot of combined bio drugs innovation’s issues [3]. Now we are in age where the bio pharmacy improves with a high rapidity, a new generation of several bio drugs is discovered for improving survival rates, a lot of chronic and even fatal maladies are promised now with a new series of bio drugs to enhance the patient health [4-7]. The role of this staff (bio pharmacists, directors, and managers) is to minimize the risks and the harm of the new developed bio drugs during the clinical trials process and during the patient’s consumption of this new treatment, also to secure the efficacy of the new bio drug and guarantee that the novel discovered bio drugs can be used safely. Moreover, to facilitate its access and also to strengthen the country’s economy in order to serve the humanity interests and boosting the healthcare progress in general [8]. However, the biopharmaceutical innovation can be seen as a junction between business and health, this gives rise to a several series of ethical and responsibility issues and a dire need to make some rules, standards and principles for the bio drug innovation’s process built on rational and virtues.","PeriodicalId":18585,"journal":{"name":"MOJ proteomics & bioinformatics","volume":"85 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2017-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"MOJ proteomics & bioinformatics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/mojpb.2017.06.00204","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Responsible research and innovation (RRI) is among the most important issues that have generated a huge debate within the political and social milieu, which became an overall case for the biggest EU Research and innovation program ever Horizon [1]. Responsible research and innovation is among the important doctrines for the sustainability of the company [2]. Ethics and the biopharmaceutical responsible innovation is a paradigm of a sector where the ethics and responsibility of health professionals is inevitably linked to public and private life. The biopharmaceutical research, development and marketing responsibilities are taken by the pharmacists, directors and managers of the biopharmaceutical company, all are a combined healthcare team which work together and have a lot of combined bio drugs innovation’s issues [3]. Now we are in age where the bio pharmacy improves with a high rapidity, a new generation of several bio drugs is discovered for improving survival rates, a lot of chronic and even fatal maladies are promised now with a new series of bio drugs to enhance the patient health [4-7]. The role of this staff (bio pharmacists, directors, and managers) is to minimize the risks and the harm of the new developed bio drugs during the clinical trials process and during the patient’s consumption of this new treatment, also to secure the efficacy of the new bio drug and guarantee that the novel discovered bio drugs can be used safely. Moreover, to facilitate its access and also to strengthen the country’s economy in order to serve the humanity interests and boosting the healthcare progress in general [8]. However, the biopharmaceutical innovation can be seen as a junction between business and health, this gives rise to a several series of ethical and responsibility issues and a dire need to make some rules, standards and principles for the bio drug innovation’s process built on rational and virtues.